Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Bio-Techne acquires Exosome Diagnostics for $250 million

by Ryan Cross
June 30, 2018 | A version of this story appeared in Volume 96, Issue 27

 

Bio-Techne will acquire Exosome Diagnostics for $250 million, plus up to $325 million in potential milestone payments. Waltham, Mass.-based Exosome currently offers a urine test to detect RNA contained in vesicles called exosomes released by prostate cancer cells. The company is also developing several tests to diagnose other cancers from exosomes released by other cells into the blood. Bio-Techne says this is its 14th acquisition in five years and its “most promising to date.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.